Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel Sells 25,000 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $28.39, for a total transaction of $709,750.00. Following the transaction, the executive vice president now owns 580,325 shares in the company, valued at approximately $16,475,426.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, September 23rd, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $26.38, for a total transaction of $659,500.00.
• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $25.79, for a total transaction of $515,800.00.

Exelixis Trading Up 2.8 %

Exelixis stock opened at $34.12 on Friday. Exelixis, Inc. has a 1-year low of $19.20 and a 1-year high of $34.45. The firm has a market capitalization of $9.74 billion, a PE ratio of 21.87, a price-to-earnings-growth ratio of 0.69 and a beta of 0.54. The firm’s 50 day simple moving average is $27.13 and its 200 day simple moving average is $24.29.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter in the previous year, the company earned $0.10 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. Research analysts forecast that Exelixis, Inc. will post 1.59 earnings per share for the current year.

Hedge Funds Weigh In On Exelixis

A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. Covestor Ltd boosted its stake in shares of Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 341 shares in the last quarter. CWA Asset Management Group LLC purchased a new stake in shares of Exelixis in the 3rd quarter valued at $577,000. Capital Performance Advisors LLP purchased a new stake in shares of Exelixis in the 3rd quarter valued at $61,000. Heritage Investors Management Corp purchased a new stake in shares of Exelixis in the 3rd quarter valued at $201,000. Finally, Capital Management Corp VA boosted its stake in shares of Exelixis by 7.5% in the 3rd quarter. Capital Management Corp VA now owns 365,270 shares of the biotechnology company’s stock valued at $9,479,000 after purchasing an additional 25,350 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on EXEL. Morgan Stanley boosted their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Stephens boosted their target price on shares of Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a research note on Wednesday. Truist Financial boosted their target price on shares of Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 13th. Finally, UBS Group started coverage on shares of Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.